Wavena

AI that predicts 30+ blood biomarkers from a 10-second ECG without a blood draw.

Cover Block

Open sources

Field	Value
Name	Wavena
Tagline	AI that predicts 30+ blood biomarkers from a 10-second ECG without a blood draw. [WOWTALE, October 2026]
Headquarters	Seoul, South Korea [VeilStrat, October 2026]
Founded	2026 [VeilStrat, October 2026]
Stage	Seed [InFor Capital, October 2026]
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed
Total Disclosed	$150,000 [InFor Capital, October 2026]

What an Investor Needs First

PUBLIC Wavena is an early-stage South Korean healthtech company developing AI that infers blood biomarker information from a 10-second ECG, a proposition that stands out because it targets a slower, invasive clinical workflow with a faster non-blood-draw alternative at a moment when the company has just secured seed backing and TIPS selection [WOWTALE, October 2026] [InFor Capital, October 2026]. Public reporting places the company in Seoul and dates its founding to 2026, with early coverage framing it as a digital-health startup built around ECG-to-biomarker prediction rather than a broader remote-care platform [VeilStrat, October 2026] [Crunchbase].

The core claim investors should focus on is narrower than the broad product narrative: multiple Korean startup and healthcare publications consistently report that Wavena has shown AUROC scores of 0.89 to 0.92 for nine key biomarkers, including hyperkalemia, renal function, anemia, and heart failure, which gives at least some third-party consistency around early technical performance even though peer-reviewed validation was not surfaced in the source set [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026]. Broader claims, including prediction of more than 30 biomarkers and a large matched ECG-blood dataset, appear in funding-distribution coverage but are less firmly corroborated, so the present public case rests more on clinical promise than on fully verified deployment evidence [Fundz, October 2026].

The initial commercial wedge appears to be nephrology and dialysis. One public report describes Wavena Medical as designed for dialysis patients, which fits the biomarker-monitoring use case and suggests a focused first market rather than an undifferentiated consumer launch [The Pharma News]. The founder identified in the materials, Yongcheol Kim, is reported to be a practicing nephrologist and clinical professor at Seoul National University Hospital, a background that is relevant to both data access and problem selection, although that biography was not independently corroborated in the public sources provided here [Fundz, October 2026].

On capitalization, the facts are straightforward. Wavena raised a seed round of about $150,000, or KRW 200 million, in October 2026 from Seoul Techno Holdings and was also selected for South Korea's TIPS program, giving the company modest but credible non-dilutive and strategic support at a very early stage [InFor Capital, October 2026] [WOWTALE, October 2026] [SignalBase, October 2026]. The business model is best understood, on current evidence, as hardware plus software in clinical settings, though public reporting still says little about pricing, regulatory sequence, reimbursement strategy, or signed customers [Crunchbase] [The Pharma News].

Over the next 12 to 18 months, the main public watchpoints are whether Wavena can convert technical claims into regulator-ready evidence, show prospective validation beyond announcement-stage metrics, and translate its dialysis-centered thesis into named clinical partners or early commercial deployments [StartupN, October 2026] [The Bio News, October 2026]. For investors, the company is interesting because the founding profile and use case are coherent, but the diligence burden remains high because most operating details, product breadth claims, and commercialization milestones are still lightly documented in public sources [Fundz, October 2026] [InFor Capital, October 2026].

Partially corroborated -- Funding, stage, and core positioning are corroborated across multiple public sources, but several material operating and team details remain supported by only one source or funding-distribution coverage.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed, total disclosed about $150,000

Inside the Company

Open sources Wavena enters the record with very little corporate scaffolding exposed, which matters because the public case for the company rests more on recent financing coverage than on long-lived company documentation. Crunchbase identifies Wavena as a Seoul, South Korea-based company, founded in 2026, and describes the business as focused on ECG-based biomarker prediction [Crunchbase]. The company website, by contrast, currently offers only minimal visible information beyond the company name, which leaves headquarters, founding date, and company description effectively reliant on database coverage rather than a fuller first-party corporate profile [Wavena].

The public milestone sequence is correspondingly short. Crunchbase lists the company as founded in 2026 and records Wavena as having raised seed funding, establishing that the business moved from formation to external financing within the same year [Crunchbase]. On the website, the available homepage does not surface a more detailed founding narrative, legal entity name, or operating history, so the chronology that can be confirmed from the allowed source set remains limited to formation and early funding visibility [Wavena] [Crunchbase].

Partially corroborated -- This section relies primarily on Crunchbase, with only minimal corroboration from the company website.

Under the Hood

MIXED

The product claim that matters most is straightforward to state and still early in its evidentiary base. Wavena is described in multiple October 2026 funding and startup press reports as developing AI that predicts more than 30 blood biomarkers from a 10-second ECG, without a blood draw [WOWTALE, October 2026] [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026]. That same press cluster also ties the company to a narrower clinical wedge, hemodialysis, with The Pharma News describing Wavena Medical as designed for dialysis patients [The Pharma News].

The technical performance detail is partly corroborated and partly not. Four Korean-language outlets reported AUROC scores of 0.89 to 0.92 for nine key biomarkers, including hyperkalemia, renal function, anemia, and heart failure, which gives the company a clearer proof point than the broader platform narrative alone [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026]. By contrast, the larger claims, a proprietary database of 4 million matched ECG and blood-sample records, continuous-value prediction with confidence intervals across more than 30 biomarkers, and a broader product family spanning consumer wellness, glucose monitoring, and animal health, appear in secondary aggregation or search-wrapper material and are not independently verified in the captured publisher set [Fundz, October 2026].

From an investor's standpoint, the technology appears more credible at the indication level than at the platform level, at least on public evidence. There is a plausible clinical logic to starting with dialysis patients, where repeated monitoring, electrolyte risk, and time sensitivity are real, but the public record still does not show a peer-reviewed validation paper, a verified product demo, regulatory clearance, or named commercial deployment [The Pharma News] [WOWTALE, October 2026]. For now, the strongest supported view is that Wavena has an ECG-based biomarker prediction model with early reported accuracy in a defined use case, while the fuller product suite should be treated as reported rather than established [StartupN, October 2026] [Fundz, October 2026].

Partially corroborated -- Core product claims are corroborated across multiple public funding reports, but several important technology and pipeline details rely on single-source or lightly verified secondary coverage.

Market Research

PUBLIC The market matters now because Wavena sits at the intersection of two expanding pools of spend, AI-enabled clinical decision support and chronic kidney disease care, but the public record is still too thin to size its exact addressable market directly from named third-party reports.

No source set here provides a cited TAM, SAM, or SOM for Wavena itself, and the available coverage is mostly funding-announcement reporting rather than sector research [WOWTALE, October 2026] [InFor Capital, October 2026]. That limits precision. The cleaner way to frame demand is through the company's stated initial wedge: dialysis centers and hemodialysis patients, where conventional blood testing is routine and time-sensitive clinical decisions carry direct operational weight [The Pharma News] [NEWSx.io, October 2026]. If Wavena's ECG-based biomarker inference proves clinically reliable in that workflow, it would be competing for budget inside nephrology monitoring and lab-adjacent decision support rather than across the full diagnostics market [StartupN, October 2026] [The Bio News, October 2026].

The near-term demand driver in the public materials is speed. Multiple reports describe Wavena's approach as predicting biomarker status from a 10-second ECG and emphasize applications for hemodialysis, where frequent assessment of electrolyte balance, renal function, anemia, and heart-failure risk is part of routine care [WOWTALE, October 2026] [StartupN, October 2026] [NewsTap, October 2026]. The strongest public validation signal is not commercial traction but performance reporting in Korean startup and biotech press, which cited AUROC results of 0.89 to 0.92 for nine biomarkers including hyperkalemia, renal function, anemia, and heart failure [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026]. That does not establish reimbursement, adoption, or clinical utility at scale, but it does explain why dialysis and high-frequency monitoring settings are the logical first market.

The adjacent markets are broader than the first use case, though the evidence weakens as the scope widens. Coverage consistently supports the core ECG-to-biomarker positioning and the dialysis focus, but pipeline references beyond that, including consumer wellness, glucose monitoring, and animal health, rest on low-confidence secondary aggregation rather than independent public verification [Fundz, October 2026]. For market interpretation, that means the investable public story remains narrower than the product ambition suggests: the relevant substitutes today are standard blood draws, point-of-care testing, and other monitoring workflows used in nephrology and cardiometabolic care, not a proven multi-vertical platform.

Regulation is likely to shape market timing as much as product performance. The cited public sources point to South Korea first, through both the company's TIPS selection and its apparent intention to build in a domestic clinical network before wider commercialization [InFor Capital, October 2026] [NEWSx.io, October 2026]. That matters because software making biomarker-related clinical inferences for dialysis patients will almost certainly face a higher evidence bar than a consumer wellness tool, especially if the output informs treatment decisions. Public reporting also points to a claimed data asset drawn from Seoul National University hospital records, which, if validated, could help with local model development, though that claim appears in secondary reporting and is not independently corroborated by a filing or peer-reviewed study in the provided materials [Fundz, October 2026].

Market lens	Public evidence	Relevance to Wavena
Dialysis and hemodialysis workflow	Initial product is described as designed for dialysis centers and hemodialysis patients [The Pharma News] [NEWSx.io, October 2026]	Suggests the first commercial market is a specialized clinical workflow with recurring monitoring needs
ECG-based biomarker prediction	Company is reported to predict over 30 blood biomarkers from a 10-second ECG [WOWTALE, October 2026]	Positions the offering as a potential substitute or triage layer ahead of some blood-test decisions
Clinical performance signal	Korean press reports AUROC of 0.89 to 0.92 for nine biomarkers [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026]	Supports technical interest, though not yet commercial adoption or reimbursement
South Korea innovation programs	Seed funding and TIPS selection were reported in October 2026 [InFor Capital, October 2026] [WOWTALE, October 2026]	Indicates public-sector support for early R&D and domestic validation

The evidence points to a definable wedge rather than a fully mapped market. What is investable at this stage is the possibility that nephrology monitoring can support a narrower, clinically urgent entry point, while any broader diagnostics or consumer expansion remains an unproven extension of that thesis.

Partially corroborated -- Section rests on multiple public funding and trade-press sources for product focus and biomarker performance, but no named third-party market-sizing reports were available in the provided materials.

Competition and Substitutes

MIXED Wavena is positioning itself against blood-based diagnostics and dialysis monitoring workflows more than against a clearly disclosed set of startup peers, which makes the current competitive picture less about named head-to-head rivals and more about which care pathway it is trying to displace or compress. [WOWTALE, October 2026] [The Pharma News]

The clearest segment map starts with incumbents in clinical chemistry and dialysis operations. For biomarker measurement, the practical baseline is still conventional blood testing processed through hospital and reference-lab workflows, because Wavena's public pitch is explicitly that a 10-second ECG can predict more than 30 blood biomarkers without a blood draw. [WOWTALE, October 2026] In the dialysis setting, the adjacent substitute is not a named software vendor in the sourced material but the status quo of periodic blood sampling, clinician review, and treatment adjustment inside nephrology centers. [The Pharma News] [NEWSx.io, October 2026]

The next layer is challengers, but the public record here is thin. None of the provided sources name a direct ECG-to-biomarker startup competitor, and the available coverage is concentrated in funding and startup press rather than comparative clinical reporting. [InFor Capital, October 2026] [Fundz, October 2026] That absence does not mean the field is empty. It means Wavena's disclosed competitive set is still being framed through the problem it addresses, namely faster and less invasive decision support for hemodialysis patients, rather than through public contests with named companies. [The Pharma News] [WOWTALE, October 2026]

Where Wavena appears strongest today is in the combination of clinical-domain focus and claimed data access. Multiple October 2026 reports say the company achieved AUROC scores of 0.89 to 0.92 across nine key biomarkers, including hyperkalemia, renal function, anemia, and heart failure, which is more specific than a generic AI-diagnostics claim and points to a narrowly chosen first wedge in nephrology. [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026] Fundz also reported a proprietary database of 4 million matched ECG and blood-sample records from Seoul National University hospitals, although that database claim is not independently corroborated by a filing or peer-reviewed paper in the provided materials. [Fundz, October 2026]

That edge could be durable if the underlying dataset is both exclusive and clinically current, because nephrology-specific model performance tends to depend on repeated measurements in a tightly defined patient population. [Fundz, October 2026] [The Pharma News] It is also a perishable advantage. Clinical AI leads narrow quickly if the data cannot be converted into regulatory clearance, published validation, and embedded hospital workflow, and the public sources here do not yet show named commercial deployments, approved products, or peer-reviewed evidence. [NEWSx.io, October 2026] [InFor Capital, October 2026]

The company is most exposed where incumbents already own trust, reimbursement context, and workflow control. Standard blood testing remains the reference method for the biomarkers Wavena says it can predict, so any buyer will compare ECG-inferred values against lab-grade measurements rather than against another early-stage startup. [WOWTALE, October 2026] That makes the competitive hurdle partly scientific and partly operational: even with encouraging AUROC figures, Wavena still has to show when an ECG-derived estimate is good enough to change care in dialysis settings. [StartupN, October 2026] [The Bio News, October 2026]

There is also a channel risk embedded in the current public narrative. The sources point to dialysis centers and hemodialysis patients as the first application, but they do not identify a signed hospital customer, a device OEM relationship, or a distribution partner that would help the product move beyond pilots and affiliated clinical networks. [The Pharma News] [NEWSx.io, October 2026] In competitive terms, that leaves room for better-capitalized diagnostics, monitoring, or medical-device companies to absorb similar models into channels they already control, even if those companies are not named in the present source set.

Over the next 18 months, the most plausible competitive scenario is that the category sorts first by evidence, not by brand. Wavena is the likely winner if its reported nephrology performance can be reproduced in prospective validation and translated into MFDS-facing regulatory progress, because the current story already has a coherent first use case and investor support through a seed round and TIPS selection. [InFor Capital, October 2026] [WOWTALE, October 2026] The likely loser if that evidence does not arrive is not necessarily a named startup rival, but the broader ECG-as-biomarker-prediction thesis in dialysis triage, because buyers will default back to conventional lab workflows until a company demonstrates that speed gains also hold clinical reliability. [WOWTALE, October 2026] [StartupN, October 2026]

Partially corroborated -- Section relies on multiple public funding and Korean startup press sources for Wavena's positioning and performance claims, but no named direct competitors were confirmed in the provided materials, and key differentiation points such as the 4 million-record database remain single-source or unverified.

Opportunity

PUBLIC

The prize here is not a marginally better diagnostic workflow, but a new front door for lab-adjacent monitoring if ECG can reliably stand in for parts of blood testing in high-frequency care settings such as dialysis [WOWTALE, October 2026] [StartupN, October 2026] [The Pharma News].

The headline opportunity is straightforward. If Wavena can turn a 10-second ECG into clinically credible biomarker inference for a narrow but recurring use case, it could become the monitoring layer that sits between vital-sign capture and lab escalation in nephrology care, beginning with dialysis centers and potentially extending to other settings where repeated bloodwork is slow, invasive, or operationally heavy [WOWTALE, October 2026] [The Pharma News]. That outcome is still early, but it is not purely aspirational on the current record: multiple Korean outlets attribute to the company AUROC scores of 0.89 to 0.92 for nine key biomarkers, including hyperkalemia, renal function, anemia, and heart failure, and the company has already secured seed financing plus selection into South Korea's TIPS program, which at minimum suggests external screening by capital and public-program gatekeepers [StartupN, October 2026] [The Bio News, October 2026] [KMNANews, October 2026] [NewsTap, October 2026] [InFor Capital, October 2026].

The upside path is best thought of as a set of staged commercialization outcomes rather than a single all-or-nothing bet. The evidence base is still thin, so each path turns on execution milestones that are visible enough to name now.

Scenario	What happens	Catalyst	Why it's plausible
Dialysis workflow standard	Wavena Medical becomes routine decision-support inside Korean dialysis centers, with ECG-based biomarker prediction used to flag patients who need faster intervention or confirmatory testing	Clinical validation in hemodialysis and progress toward domestic regulatory review	The initial product is specifically described as targeting dialysis centers and hemodialysis patients, and the biomarker set cited in coverage maps closely to nephrology-relevant monitoring needs [The Pharma News] [StartupN, October 2026] [NewsTap, October 2026]
Data-and-model leader in ECG-to-biomarker inference	The company uses its clinical dataset to become the reference model provider for ECG-based biochemical estimation across hospital partners	Continued dataset expansion and repeatable performance across additional biomarkers	Fundz reports a proprietary database of 4 million matched ECG and blood-sample records from Seoul National University hospitals, while multiple outlets report strong AUROC performance for nine biomarkers, which together at least sketch a data advantage if independently validated later [Fundz, October 2026] [StartupN, October 2026] [The Bio News, October 2026]
Platform expansion beyond nephrology	After proving one clinical wedge, Wavena extends the same inference layer into adjacent products, potentially spanning consumer wellness or other monitoring surfaces	A successful first clinical deployment that de-risks the core algorithm and attracts device or distribution partners	Secondary coverage describes a broader product pipeline beyond Wavena Medical, including a consumer application, which indicates management is framing the technology as a platform rather than a single-feature tool, even if those adjacent products remain unverified commercially [InFor Capital, October 2026] [Fundz, October 2026]

The table points to a familiar compounding pattern in applied health AI. One validated use case can improve data access, clinician trust, and model tuning at the same time, especially when the target population generates repeat measurements. Here, the early signs of that flywheel are the reported concentration on dialysis, the claimed matched ECG and blood dataset, and the company's TIPS-backed development path, which public coverage says is tied to advancing R&D around hemodialysis applications [The Pharma News] [Fundz, October 2026] [NEWSx.io, October 2026]. If that loop holds, each additional site could improve model calibration, which could improve clinical utility, which could in turn make the next site easier to win. In this category, the moat is less likely to be the model architecture alone than the pairing of workflow integration and accumulated labeled clinical data.

The size of the win is difficult to pin down because no credible public market-sizing source was provided in the source set, and no direct public comparable was cited. Even so, the strategic value can be framed conditionally. If Wavena were to become a recognized clinical infrastructure layer for ECG-based biomarker inference in dialysis and related care pathways, the company would likely be valued more like a regulated clinical software and data platform than a single-feature device company (scenario, not a forecast). The current public evidence does not support a numeric valuation range, but it does support the claim that this could become a category-level asset if the reported performance for nine biomarkers translates into repeatable clinical deployment and regulatory progress [StartupN, October 2026] [The Bio News, October 2026] [InFor Capital, October 2026].

Partially corroborated -- This section relies mainly on Korean press coverage and funding-distribution reports, with partial cross-corroboration on funding, TIPS selection, dialysis focus, and nine-biomarker performance. Broader platform and dataset claims remain only partially verified in public sources.

Sources